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Impairment of pulmonary diffusion is recognized following heart transplantation. This study was undertaken 
to determine the histopathological basis for the defect in pulmonary physiology. Heart transplant recipients 
(HTR) entered into a prospective study of post-transplant pulmonary physiology were asked to undergo 
bronchoscopy, bronchoalveolar lavage (BAL) and transbronchial biopsy (n= 18) in the presence of impaired 
gas transfer. Transbronchial biopsies were examined under light microscopy and demonstrated focal 
interstitial fibrosis in 12 patients, cytomegalovirus disease in four patients and Pneumocystis carinii pneumonia 
in three patients. Bronchoalveolar lavage differential counts were normal in HTR but BAL macrophages 
contained haemosiderin. The histological features of interstitial fibrosis may underlie the fall in gas transfer 
seen following heart transplantation. The presence of haemosiderin-laden macrophages late following heart 
transplantation suggests a capillary leak syndrome. 
Introduction 
A number of studies of lung function following 
heart transplantation have shown a consistent reduc- 
tion in diffusion coefficient (X0) following surgery 
(1,2). Similar changes have been documented in renal 
transplant recipients (3) implying a common cause 
related to the process of-transplantation (i.e. immu- 
nosuppression or infection), rather than the effects of 
impaired cardiac function or surgery. The present 
authors have previously identified cytomegalovirus 
(CMV) infection as being associated with a reduced 
gas transfer following heart transplantation (4), but 
other proposed causes include cyclosporin (5). To 
further assess the fall in gas transfer, heart transplant 
recipients (HTR) were asked to undergo broncho- 
alveolar lavage (BAL) and transbronchial biopsy 
(TBB). In light of a previous observation of high 
levels of haemosiderin-laden macrophages in a small 
number of HTR studied as a part of a larger group of 
patients (6) the BAL haemosiderin scores were 
derived. 
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Patients and Methods 
PATIENTS 
Eighteen HTR (16 male, two female, mean age 52 
years) underwent lung function and consented to 
BAL and TBB, and a further two consented to BAL 
without TBB. Ethical approval was obtained from 
South Manchester University Hospitals Trust Ethical 
Committee. 
LUNG FUNCTION 
The following parameters were measured at a 
mean of 152 days (range 62-331 days) following 
transplantation: forced expiratory volume in 1 s 
(FEV,); forced vital capacity (FVC); residual volume 
(RV); functional residual capacity (FRC) (Gould 
Pulmonet 111 wet spirometer); maximal inspiratory 
and expiratory flow volume loop; total lung capacity 
(TLC) (Jaeger Body Plethysmograph); single breath 
carbon monoxide diffusion (DLCO) and gas transfer 
coefficient (KCO) (PK Morgan transfer test). The 
definitions and methods for performing lung volumes 
and diffusing capacity follow the recommendations 
of the European Community for Coal and Steel (78). 
DLCO values were corrected for haemoglobin. 
BRONCHOSCOPIES 
Flexible bronchoscopy (FB) was undertaken at a 
mean of 157 days (range 49-318 days). No patient 
had evidence of graft rejection or a coagulopathy at 
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the time of TBB. Flexible bronchoscopy was carried 
out with intravenous sedation (midazolam) and topi- 
cal local anaesthesia (2% lignocaine via the broncho- 
scope). Bronchoalveolar lavage was undertaken with 
the bronchoscope in a subsegment of the right middle 
lobe. Instillation of 2 x 50 ml aliquots of saline was 
followed by gentle aspiration. The lavage was trans- 
ported on ice to the laboratory and processed within 
2 h. Two TBB were obtained from each lobe under 
radiographic screening. There were no complications 
of either pneumothorax or excess haemorrhage in 
any of the 18 patients. 
CMV SURVEILLANCE 
Cytomegalovirus (CMV) antibody status of the 
organ donor and recipient were determined prior to 
transplantation (CMV-scan; Becton Dickenson). 
Post-operatively, CMV surveillance involved routine 
virus culture and serology. Cytomegalovirus-specific 
IgG and IgM antibody were detected by enzyme 
immunoassay. Bronchoalveolar lavage specimens 
were examined for CMV by the detection of direct 
early antigen fluorescent foci (DEAFF test) using a 
monoclonal antibody (6A2 anti-immediate early gene 
product) (9) in addition to the routine culture of 
the BAL, by inoculation onto human embryonic 
fibroblasts, and examined for cytopathic effect. 
HISTOLOGY 
The TBB were processed using a Shandon Tissue 
Processor and then fixed in paraffin wax. Levels 5,~ 
thick were cut, placed on slides and stained with 
haematoxylin and eosin. Two tissue sections were 
stained specifically using a monoclonal antibody 
directed against cytomegalovirus (mouse monoclonal 
antibody, Dackopatts, Copenhagen, Denmark). The 
sections were examined for Pneumocystis cavinii 
pneumonia (PCP) with antiserum (mouse anti- 
serum antibody, M778, Dackopatts, Copenhagen, 
Denmark). Elastic Van Geisons and Methenamine 
Silver stains were also carried out. 
HAEMOSIDERIN SCORES 
Bronchoalveolar lavage fluid was processed for 
evidence of alveolar haemorrhage. Two cytocentri- 
fuged slides were stained by Prussian Blue. The 
haemosiderin content of alveolar macrophages were 
scored according to the following scale: O=no colour, 
1 =faint blue, 2=medium intensity blue <50%, 
3 = deep blue > 50%, 4 = deep blue throughout the cell, 
as described previously (10). The haemosiderin score 
(HS) was determined by counting 200 scored macro- 
phages and dividing by two. Low haemosiderin 
scores were defined as ~50. Intermediate scores were 
defined as >50 < 100. High scores were defined as 
> 100 (10). 
STATISTICS 
The percentage of predicted of the FEV,, TLC, 
DLCO and KC0 pre- and post-transplant were com- 
pared using a paired Student’s t-test. Two-tailed 
probability was used and significance was set at the 
95% level. 
Results 
LUNG FUNCTION (TABLE I) 
The mean % predicted FEV, did not fall following 
transplantation (pre-transplant, 75% range 36-97; 
post-transplant 74%, range 622100, SE 3.7, P=O.8). 
Neither did the mean % predicted TLC change after 
transplantation (pre-transplant 90%, range 61-99; 
post transplant, 82%, range 61-109, SE 3.2, P=O.4). 
The mean % predicted DLCO fell significantly follow- 
ing tranplantation (pre-transplant, 68%, range 39-98; 
post-transplant 50%, range 35-72, SE 3.5, P=O.OOOl). 
The mean % predicted KC0 also fell significantly 
following transplantation (pre-transplant, 88%, range 
42-154, post-transplant, 63%, range 29985, SE 5.5, 
P=O.O003). 
HISTOPATHOLOGY (TABLE 2) 
Twelve of the 18 patients who underwent trans- 
bronchial biopsies had focal interstitial fibrosis 
(Plate 1). Three patients (Patients, 15-17) had CMV 
pneumonitis (viral inclusions plus inflammatory infil- 
trate). Patient 16 also had.PCP as did two others; 
Patients 9 and 12. Patient 10 had viral inclusions but 
no inflammatory infiltrate and, at post mortem, had 
CMV duodenitis. Patient 12 died from pancreatitis in 
association with PCP. The chest radiograph was 
normal in all patients except Patients 9, 12 and 16. 
INFECTION (TABLE 2) 
All patients with histological evidence of CMV 
disease were BAL DEAFF test positive, as was one 
patient with PCP. One patient grew Herpes simplex. 
HAEMOSWERIN SCORES 
Haemosiderin scores were available on 18 of the 20 
HTR who underwent FB and BAL (the slides from 
Patients 12 and 15 were unsuitable for staining). Four 
patients had low haemosiderin scores, two had 
intermediate scores and 11 patients had high scores 
(Table 2, Plate 2). 
Discussion 
The frequent finding of interstitial fibrosis and 
haemosiderin-laden macrophages (high haemosiderin 
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Table I Lung function before and after heart transplantation 
Patients FEV, 
Pre-transplant 
TLC DLCO KC0 FEV, 
Post-transplant 
TLC DLCO KC0 
1 97 98 79 100 100 89 50.7 68 
2 86 85 42 54 86 96 48 52 
3 78 90 98 100 90 83 55 72 
4 60 87 39 56 65 74 38 50 
5 70 81 46 74 83 85 55 77 
6 63 90 98 154 65 72 72 85 
7 92 112 56 50 82 89 56 74 
8 60 84 73 92 72 76 40 62 
9 36 61 62 125 66 73 35 48 
10 64 98 45 42 62 90 30 29 
11 89 99 62 71 89 109 60 62 
12 71 90 89 114 65 97 56 74 
13 82 92 87 100 75 80 67 65 
14 90 91 68 79 58 61 38 61 
15 * * * * 69 74 37 45 
16 96 85 82 107 54 50 42 73 
17 72 98 73 90 75 75 55 62 
18 68 77 76 121 84 94 66 81 
19 90 93 72 84 93 96 57 62 
20 75 99 52 64 62 81 45 60 
Lung function in percentage of predicted. FEV,, forced expiratory volume in 1 s; TLC, total 
lung capacity; DLCO, single breath carbon monoxide diffusion; KCO, gas transfer coefficient. 
*Lung function unavailable. 
Table 2 Summary of histology and haemosiderin scores of heart transplant recipients 
Patient 
Interstitial 
fibrosis 
CMV 
inclusions 
Viral 
culture PCP HS DPT 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
Yes No 
Yes No 
Yes No 
No No 
Yes No 
Yes No 
Yes No 
Yes No 
Yes NO 
Yes Yes 
Yes No 
Yes No 
No No 
Yes No 
No Yes 
No Yes 
No Yes 
Yes No 
* * 
* * 
NV1 No 66 331 
NV1 No 144 215 
NV1 No 84 304 
NV1 No 145 194 
NV1 No 159 160 
NV1 No 177 173 
NV1 No 57 174 
NV1 No 3 62 
NV1 Yes 2 156 
DEAFF+ No 180 48 
NV1 No 126 197 
DEAFF+ Yes * 69 
NV1 No 185 109 
NV1 No 0 80 
DEAFF + No * 86 
DEAFF + Yes 115 149 
DEAFF + No 207 5x 
NV1 No 0 89 
H. simplex * 260 202 
NV1 9 168 187 
HS, haemosiderin score; PCP, Pneumocystis car&ii pneumonia; CMV, cytomegalovirus; DPT, 
days post-transplant; NVI, No virus isolated; DEAFF, direct early antigen fluorescent foci; 
H. simplex, Herpes simplex. *, not available. 
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Plate I Interstitial fibrosis within lung tissue obtained by 
transbronchial biopsy. 
Plate 2 Macrophage staining with Prussion Blue, indicat- 
ing the presence of haemosiderin. 
scores) offers a potential explanation for the diffusion 
impairment seen in the lungs of patients late follow- 
ing heart transplantation. Although the present 
authors have previously identified CMV as a risk 
factor for a reduced transfer factor following trans- 
plantation, only four patients in the present series 
had histological evidence of CMV disease. 
Therefore, what are the potential causes of a 
reduced gas transfer, interstitial fibrosis and 
haemosiderin-laden macrophages following heart 
transplantation? These findings could be due to pre- 
transplant pulmonary venous hypertension since all 
the patients were in NYHA Class 4 heart failure prior 
to transplantation. The majority of other studies 
relating to the structural changes in the lung associ- 
ated with pulmonary venous hypertension are in 
mitral stenosis. Initially, in mitral stenosis, there is 
thickening of the alveolar interstitium from oedema 
and then from fibrosis. In addition, the endothelial 
cells of the pulmonary capillary become oedematous, 
swollen and accumulate haemosiderin (11). With this 
persistent oedema, the alveolar capillaries become 
embedded in dense connective tissue (11). 
However, there is little data on the microvascularl 
alveolar structure of the lung following the resolution 
of pulmonary venous hypertension. A number of 
reports document a reduction in the medial hyper- 
trophy of pulmonary arteries and interstitial fibrosis 
in patients who had a lung biopsy at the time of 
mitral valvotomy and whose lung was examined 
subsequently at autopsy (12). Therefore, the changes 
within the lung late following HT when pulmonary 
artery pressures are normal suggests that some factor 
other than pre-transplant pulmonary venous hyper- 
tension may cause the histological changes in the 
lung late following transplant. This is emphasized by 
the contrasting changes which occur in lung physi- 
ology following heart transplantation in comparison 
to the lung physiology following mitral valve repair. 
After heart transplantation, there is a fall in diffusion 
capacity (4,5) in spite of restoration of normal 
haemodynamics, whereas following mitral valve 
repair, the lung physiology remains the same (13) or 
improves (14) despite persistently raised pulmonary 
artery pressures (13). 
High haemosiderin scores after heart transplanta- 
tion may also reflect alveolar haemorrhage from 
congestive cardiac failure prior to transplantation. 
However, studies examining transferin excretion 
from the lungs of patients with mitral stenosis and 
patients with chronic pulmonary venous hyperten- 
sion due to left heart failure have shown that these 
lungs are efficient at protecting themselves from the 
effects of heart failure (15). This protective phenom- 
enon is considered to be the result of either increased 
thickening of the endothelial alveolar membrane 
and/or improved adaptive lymphatic systems within 
the lungs. This evidence suggests that the raised 
haemosiderin levels within the lung at a mean of 157 
days after transplantation are the result of a new 
injury and not just the persistence of a pre-transplant 
phenomenon. 
An alternative possible explaination for the histo- 
logical findings within the lung is that it results from 
cyclosporin therapy. Cyclosporin is known to cause 
interstitial fibrosis and microvascular changes within 
the kidney (16). These renal changes take two histo- 
logical patterns; either an arteriolaropathy with 
narrowing of the vascular lumen or an interstitial 
fibrosis. Although arteriolar hyalinosis, recognized in 
cyclosporin-induced renal injury, was not observed 
(17), one might speculate that the histological 
changes in the kidney following cyclosporin have 
some similarity to the histological changes seen in 
the lungs of these patients studied late following 
heart transplantation. Renal transplant patients 
receiving cyclosporin are also recognized as having 
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abnormalities in pulmonary diffusion (3), suggesting 
that the physiological changes in HTR are related to 
infection or immunosuppression rather than the 
effects of heart failure and surgery. However, a causal 
relationship between cyclosporin and the pulmonary 
interstitial fibrosis would be difficult to prove. 
In summary, the native lungs of HTR histo- 
logically show interstitial fibrosis and evidence of 
ongoing alveolar capillary leakage at a time when no 
infective/neoplastic process is evident. These features 
may underlie the fall in gas transfer seen following 
heart transplantation. The histological changes seen 
in these lungs mimic the interstitial and vascular 
changes induced by cyclosporin in kidneys, but a 
causal relationship cannot be established by this 
study. 
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